Adverse Effects with Finasteride 5 mg/Day for Patterned Hair Loss in Premenopausal Women

    January 2018 in “ International Journal of Trichology ”
    Rui Oliveira-Soares, Marisa C André, M Peres-Correia
    Studysummary Taking 5 mg/day finasteride can cause side effects in women with hair loss, but these are usually mild and fade over time, making the treatment beneficial in the long run.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on ijtrichology.com →
    Discuss this study in the Community →

    Research cited in this study 13

    1. Organic Causes of Erectile Dysfunction in Men Under 40 Urologia Internationalis · 2013
    2. Finasteride 5 mg/Day Treatment of Patterned Hair Loss in Normo-Androgenetic Postmenopausal Women International Journal of Trichology · 2013
    3. 5 mg/Day Finasteride Treatment for Normoandrogenic Asian Women with Female Pattern Hair Loss Journal of The European Academy of Dermatology and Venereology · 2010
    4. Effect of Finasteride 5 mg (Proscar) on Acne and Alopecia in Female Patients with Normal Serum Levels of Free Testosterone Gynecological Endocrinology · 2007
    5. Relative Safety and Efficacy of Finasteride for Treatment of Hirsutism Annals of Pharmacotherapy · 2004
    6. Female Androgenetic Alopecia Treated by Finasteride: A Case Study Acta dermato-venereologica · 2004
    7. Finasteride Treatment of Patterned Hair Loss in Normoandrogenic Postmenopausal Women Dermatology · 2004
    8. Hair Loss in Women with Hyperandrogenism: Four Cases Responding to Finasteride Journal of The American Academy of Dermatology · 2002
    9. Finasteride for Female Androgenetic Alopecia British Journal of Dermatology · 2002
    10. Lack of Efficacy of Finasteride in Postmenopausal Women with Androgenetic Alopecia Journal of The American Academy of Dermatology · 2000
    11. The Effects of Finasteride on Scalp Skin and Serum Androgen Levels in Men with Androgenetic Alopecia Journal of The American Academy of Dermatology · 1999
    12. Finasteride in the Treatment of Men with Androgenetic Alopecia Journal of The American Academy of Dermatology · 1998
    13. Clinical and Hormonal Effects of the 5 Alpha-Reductase Inhibitor Finasteride in Idiopathic Hirsutism The Journal of Clinical Endocrinology and Metabolism · 1994

    Related research 10

    1. What's New in Therapy for Male Androgenetic Alopecia? American Journal of Clinical Dermatology · 2022
    2. Clinical Observation of Basic Fibroblast Growth Factor (bFGF) Combined with Minoxidil in the Treatment of Male Androgenetic Alopecia Journal of Cosmetic Dermatology · 2022
    3. Efficacy and Safety of Topical Finasteride Spray Solution for Male Androgenetic Alopecia: A Phase III, Randomized, Controlled Clinical Trial Journal of The European Academy of Dermatology and Venereology · 2021
    4. Efficacy of Intralesional and Oral Dutasteride in the Treatment of Androgenetic Alopecia: A Systematic Review Skin appendage disorders · 2020
    5. A Randomized, Double-Blind Controlled Study of the Efficacy and Safety of Topical Solution of 0.25% Finasteride Admixed with 3% Minoxidil vs. 3% Minoxidil Solution in the Treatment of Male Androgenetic Alopecia Journal of The European Academy of Dermatology and Venereology · 2018
    6. Differences in Reproductive Toxicology Between Alopecia Drugs: An Analysis on Adverse Events Among Female and Male Cases Oncotarget · 2016
    7. 5α-Reductase Inhibitors in Androgenetic Alopecia Current Opinion in Endocrinology, Diabetes and Obesity · 2014
    8. Persistent Sexual, Emotional, and Cognitive Impairment Post-Finasteride American Journal of Men's Health · 2014
    9. Evaluation of Efficacy and Safety of Finasteride 1 mg in 3177 Japanese Men with Androgenetic Alopecia Journal of Dermatology · 2011
    10. Finasteride in the Treatment of Androgenetic Alopecia Expert Opinion on Pharmacotherapy · 2004